PharmaLundensis AB (XSAT:PHAL) EBIT: kr-7.01 Mil (TTM As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

PharmaLundensis AB XSAT:PHAL

What is PharmaLundensis AB EBIT?

PharmaLundensis AB XSAT:PHAL 25 EBIT is kr-7.01 Mil as of Mar. 2026. GuruFocus rates XSAT:PHAL with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

PharmaLundensis AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-1.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-7.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PharmaLundensis AB's annualized ROC % for the quarter that ended in Mar. 2026 was -54.34%. PharmaLundensis AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,631.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PharmaLundensis AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -29.31%.

PharmaLundensis AB (XSAT:PHAL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PharmaLundensis AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-6.052 * ( 1 - 0% )	/	( (11.151	+	11.123)	/ 2 )
=	-6.052	/	11.137
=	-54.34 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.945	-	0.583	-	( 1.164	-	max(0, 4.322	-	1.533	+	1.164	))
=	11.151

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.465	-	0.507	-	( 1.969	-	max(0, 4.487	-	2.322	+	1.969	))
=	11.123

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PharmaLundensis AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.052	/	( ( (0.243 + max(-1.358, 0))	+	(0.217 + max(-1.516, 0)) )	/	2 )
=	-6.052	/	( ( 0.243	+	0.217 )	/	2 )
=	-6.052	/	0.23
=	-2,631.30 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	-0.00099999999999989)	-	(0.583	+	0	+	0.774)
=	-1.358

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.00099999999999989)	-	(0.507	+	0	+	1.01)
=	-1.516

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PharmaLundensis AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-7.014	/	23.934
	=	-29.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaLundensis AB EBIT Related Terms

PharmaLundensis AB EBIT Historical Data

* Premium members only.

The historical data trend for PharmaLundensis AB's EBIT can be seen below:

PharmaLundensis AB EBIT Chart

PharmaLundensis AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-2.20

-2.83

-3.89

-3.28

-6.86

PharmaLundensis AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-1.36	-2.01	-1.64	-1.86	-1.51

XSAT:PHAL vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, PharmaLundensis AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaLundensis AB EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's EV-to-EBIT falls into.

Save Embed

25GF Score

PharmaLundensis AB XSAT:PHAL

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmaLundensis AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.01 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of kr-7.01 Mil mean?

PharmaLundensis AB (XSAT:PHAL) has a EBIT of kr-7.01 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PharmaLundensis AB.

Is PharmaLundensis AB's EBIT too high?

PharmaLundensis AB's current EBIT is kr-7.01 Mil. Overall, PharmaLundensis AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does PharmaLundensis AB's EBIT compare to VRTX and REGN?

PharmaLundensis AB's EBIT of kr-7.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PharmaLundensis AB. PharmaLundensis AB's current EBIT is kr-7.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmaLundensis AB stock overvalued right now?

PharmaLundensis AB (XSAT:PHAL) has a current EBIT of kr-7.01 Mil. The current EBIT is kr-7.01 Mil. PharmaLundensis AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For PharmaLundensis AB (XSAT:PHAL), the current EBIT is kr-7.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaLundensis AB Business Description

Industry Healthcare Biotechnology

Comparable Companies XSAT:NIDHOG XSAT:APTA OSTO:EXPRS2 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX INCY INSM HKSE:02269

Address PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63

Website http://www.pharmalundensis.se

PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

25GF Score

Get the complete analysis for XSAT:PHAL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32

Price

View XSAT:PHAL Analysis

See EBIT data for all stocks →